Hospital
Ohiohealth Corporation
Ohiohealth Corporation was paid $76.95M by Medicaid between Jan 2018 and Dec 2024, across 430 billing codes. Its largest line is 99284, emergency room visit (serious) — 11% of everything it billed.
33Billing provider infoOHIOHEALTH CORPORATION
COLUMBUS, OH 43214
COLUMBUS, OH 43214
33aNPI1467484972assigned 07/07/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$76.95M
24GClaims1,404,736
24DCodes billed430
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#13 of 101
Median peer was paid$22.32M
This provider vs. median3.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BROWNING, MICHAEL controls 15+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 122,512 | $6.89M | |
| 2019 | 119,741 | $5.85M | |
| 2020 | 79,787 | $5.19M | |
| 2021 | 87,717 | $4.79M | |
| 2022 | 112,633 | $6.95M | |
| 2023 | 534,734 | $33.36M | |
| 2024incomplete | 347,612 | $13.92M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 48,048 | 42,550 | $8.64M |
| J2350 | Injection, ocrelizumab, 1 mg | 11% | 379 | 281 | $8.21M |
| J2323 | Injection, natalizumab, 1 mg | 8.8% | 1,221 | 1,064 | $6.76M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.3% | 31,692 | 27,516 | $6.37M |
| 96361 | Intravenous infusion, hydration; each additional hour | 7.7% | 20,294 | 13,502 | $5.90M |
| G0378 | Hospital observation service, per hour | 5.0% | 47,036 | 20,666 | $3.87M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.8% | 25,712 | 23,049 | $3.67M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 7,188 | 5,871 | $1.73M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 2.2% | 8,938 | 8,080 | $1.67M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 6,599 | 5,390 | $1.47M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 6,561 | 5,050 | $1.41M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.5% | 1,982 | 1,730 | $1.12M |
418 more codes
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.4% | 5,867 | $1.08M |
| 59025 | Fetal non-stress test | 1.3% | 5,084 | $1.01M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,721 | $767K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,949 | $665K |
| 97803 | <1% | 8,174 | $657K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,471 | $627K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,323 | $614K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,728 | $500K |
| H2020 | Therapeutic behavioral services, per diem | <1% | 3,280 | $489K |
| 58661 | <1% | 172 | $468K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,672 | $465K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,430 | $464K |
| 93976 | <1% | 2,999 | $456K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,517 | $404K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,748 | $399K |
| 70496 | <1% | 1,491 | $396K | |
| 64483 | <1% | 695 | $395K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,103 | $391K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,400 | $367K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 39,759 | $357K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,073 | $336K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,429 | $336K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,108 | $323K |
| 80053 | Comprehensive metabolic panel | <1% | 25,770 | $285K |
| 36415 | Collection of venous blood by venipuncture | <1% | 124,430 | $271K |
| 58571 | <1% | 87 | $269K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,830 | $268K |
| 78431 | <1% | 482 | $253K | |
| 96415 | <1% | 687 | $234K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,452 | $229K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,236 | $228K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 22,786 | $228K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,290 | $224K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,636 | $190K |
| 93797 | <1% | 2,615 | $189K | |
| 97802 | <1% | 1,817 | $187K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,596 | $186K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 6,572 | $185K |
| 93970 | <1% | 1,141 | $181K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 34,330 | $173K |
| 36223 | <1% | 108 | $161K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 238 | $157K |
| 36226 | <1% | 165 | $155K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 25,768 | $153K |
| 76642 | <1% | 1,059 | $149K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 606 | $148K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,023 | $148K |
| 76820 | <1% | 1,599 | $148K | |
| 72141 | <1% | 950 | $147K | |
| 47562 | <1% | 44 | $144K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,484 | $143K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,930 | $142K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 950 | $139K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,018 | $135K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,084 | $134K |
| 70491 | <1% | 442 | $133K | |
| 86900 | <1% | 5,895 | $132K | |
| 22551 | <1% | 33 | $131K | |
| 71045 | Radiologic examination, chest; single view | <1% | 17,708 | $131K |
| 76821 | <1% | 1,316 | $130K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 106 | $130K |
| 58558 | <1% | 95 | $129K | |
| 72100 | <1% | 2,296 | $128K | |
| 76536 | <1% | 1,037 | $128K | |
| 93458 | <1% | 110 | $124K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 848 | $124K |
| 93971 | <1% | 1,458 | $123K | |
| 70498 | <1% | 1,656 | $122K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 6,086 | $118K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 16,596 | $117K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,377 | $116K |
| 76830 | Ultrasound, transvaginal | <1% | 2,236 | $116K |
| 62323 | <1% | 252 | $116K | |
| 73221 | <1% | 486 | $111K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 96,507 | $107K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 542 | $107K |
| 93798 | <1% | 2,189 | $107K | |
| 99152 | <1% | 2,112 | $98K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 611 | $94K |
| 88307 | <1% | 881 | $91K | |
| 82805 | <1% | 3,324 | $91K | |
| 97162 | <1% | 2,030 | $90K | |
| J3490 | Unclassified drugs | <1% | 8,088 | $90K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,898 | $89K |
| 84484 | <1% | 14,373 | $88K | |
| 76801 | <1% | 1,630 | $87K | |
| 93017 | <1% | 952 | $87K | |
| 96376 | <1% | 7,275 | $83K | |
| 97166 | <1% | 1,888 | $83K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 907 | $82K |
| 97116 | <1% | 2,476 | $81K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,282 | $77K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 830 | $76K |
| 71250 | <1% | 914 | $73K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,725 | $72K |
| 93296 | <1% | 3,268 | $72K | |
| 80051 | <1% | 23,632 | $67K | |
| 95716 | <1% | 74 | $66K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,313 | $65K |
| 85027 | <1% | 15,734 | $60K | |
| 72131 | <1% | 894 | $60K | |
| 70486 | <1% | 938 | $60K | |
| 86850 | <1% | 5,557 | $59K | |
| 73560 | <1% | 2,064 | $59K | |
| 96367 | <1% | 1,153 | $59K | |
| 76770 | <1% | 339 | $59K | |
| 73030 | <1% | 1,708 | $58K | |
| 64493 | <1% | 95 | $57K | |
| 95700 | <1% | 363 | $57K | |
| 97129 | <1% | 1,552 | $55K | |
| 72040 | <1% | 968 | $55K | |
| 74174 | <1% | 574 | $55K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 267 | $53K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 64 | $51K |
| 96125 | <1% | 243 | $49K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,023 | $49K |
| 93299 | <1% | 1,898 | $48K | |
| 88341 | <1% | 604 | $48K | |
| 94660 | <1% | 352 | $48K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 46 | $46K |
| 97165 | <1% | 824 | $45K | |
| 97161 | <1% | 803 | $45K | |
| 97163 | <1% | 1,158 | $42K | |
| 81001 | <1% | 45,375 | $39K | |
| 72050 | <1% | 594 | $39K | |
| 77336 | <1% | 288 | $38K | |
| 73130 | <1% | 1,558 | $37K | |
| 82077 | <1% | 8,355 | $37K | |
| 10060 | <1% | 213 | $35K | |
| 76641 | <1% | 173 | $35K | |
| 73502 | <1% | 1,195 | $33K | |
| 73630 | <1% | 1,495 | $33K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,404 | $33K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,064 | $32K |
| 74018 | <1% | 841 | $32K | |
| 97130 | <1% | 1,483 | $32K | |
| 93922 | <1% | 447 | $31K | |
| 95816 | <1% | 189 | $30K | |
| 85610 | <1% | 8,810 | $29K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 18,551 | $28K |
| 20930 | <1% | 53 | $28K | |
| 73700 | <1% | 232 | $28K | |
| 77062 | <1% | 584 | $28K | |
| 74183 | <1% | 115 | $28K | |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | <1% | 522 | $28K |
| 84703 | <1% | 20,435 | $27K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 210 | $27K |
| 73610 | <1% | 1,342 | $27K | |
| 80320 | <1% | 1,593 | $27K | |
| 72146 | <1% | 325 | $26K | |
| 83605 | <1% | 6,247 | $25K | |
| 95813 | <1% | 25 | $25K | |
| 86901 | <1% | 5,892 | $24K | |
| 72110 | <1% | 387 | $24K | |
| 22853 | <1% | 37 | $24K | |
| 74178 | <1% | 83 | $23K | |
| 19083 | <1% | 32 | $23K | |
| 97167 | <1% | 720 | $23K | |
| 77300 | <1% | 33 | $23K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,949 | $22K |
| 77080 | <1% | 309 | $22K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,743 | $21K |
| 93325 | <1% | 189 | $21K | |
| 78434 | <1% | 482 | $21K | |
| 73110 | <1% | 854 | $21K | |
| 82248 | <1% | 12,319 | $21K | |
| 76377 | <1% | 1,117 | $20K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 651 | $19K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,794 | $18K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,026 | $18K |
| 72072 | <1% | 382 | $17K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,903 | $17K |
| 82565 | <1% | 24,105 | $17K | |
| 83690 | <1% | 12,670 | $17K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,004 | $17K |
| 83880 | <1% | 3,473 | $16K | |
| 92523 | <1% | 800 | $16K | |
| 77334 | <1% | 53 | $16K | |
| 90715 | <1% | 856 | $16K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 72 | $16K |
| J3535 | Drug administered through a metered dose inhaler | <1% | 1,164 | $15K |
| 94060 | <1% | 122 | $15K | |
| 82947 | <1% | 25,199 | $15K | |
| 93308 | <1% | 56 | $15K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,548 | $15K |
| 93880 | <1% | 174 | $15K | |
| 72156 | <1% | 106 | $15K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,048 | $15K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 628 | $15K |
| 62321 | <1% | 24 | $14K | |
| 72128 | <1% | 393 | $14K | |
| 80076 | <1% | 6,157 | $14K | |
| 84520 | <1% | 23,794 | $14K | |
| 80061 | Lipid panel | <1% | 1,534 | $14K |
| 64494 | <1% | 61 | $13K | |
| 83735 | <1% | 5,322 | $13K | |
| J1815 | Injection, insulin, per 5 units | <1% | 3,610 | $13K |
| 88342 | <1% | 1,186 | $13K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,220 | $12K |
| J2704 | Injection, propofol, 10 mg | <1% | 9,664 | $12K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 6,816 | $12K |
| 73080 | <1% | 580 | $12K | |
| 82607 | <1% | 1,216 | $11K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16,417 | $11K |
| 43235 | <1% | 15 | $11K | |
| 86140 | <1% | 1,721 | $11K | |
| 77061 | <1% | 201 | $11K | |
| 92610 | <1% | 503 | $11K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,150 | $10K |
| 94727 | <1% | 198 | $10K | |
| 87040 | <1% | 1,031 | $10K | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 3,716 | $10K |
| 87081 | <1% | 563 | $10K | |
| 94729 | <1% | 199 | $10K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 23 | $10K |
| 80143 | <1% | 2,143 | $9K | |
| 88304 | <1% | 582 | $9K | |
| 85730 | <1% | 2,715 | $9K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 284 | $9K |
| 73590 | <1% | 691 | $8K | |
| 87653 | <1% | 459 | $8K | |
| C1769 | Guide wire | <1% | 1,545 | $8K |
| 80179 | <1% | 2,106 | $8K | |
| 72170 | <1% | 860 | $8K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,221 | $8K |
| 96368 | <1% | 179 | $8K | |
| 81025 | <1% | 2,091 | $8K | |
| 80047 | <1% | 2,938 | $8K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 267 | $8K |
| 12001 | <1% | 68 | $8K | |
| 77066 | Tomosynthesis, mammo | <1% | 629 | $8K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,214 | $7K |
| 76870 | <1% | 262 | $7K | |
| 87077 | <1% | 1,303 | $7K | |
| 36416 | <1% | 922 | $7K | |
| 87070 | <1% | 961 | $7K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 463 | $7K |
| 76937 | <1% | 306 | $7K | |
| 82728 | <1% | 1,186 | $7K | |
| 85379 | <1% | 1,502 | $7K | |
| 84702 | <1% | 2,144 | $7K | |
| 73562 | <1% | 66 | $6K | |
| 96112 | <1% | 20 | $6K | |
| 93320 | <1% | 16 | $6K | |
| 85014 | <1% | 3,106 | $6K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 474 | $6K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,856 | $6K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 721 | $6K |
| 87506 | <1% | 51 | $6K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 14 | $5K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,515 | $5K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,255 | $5K |
| 82746 | <1% | 1,057 | $5K | |
| 84439 | <1% | 793 | $5K | |
| 85652 | <1% | 1,696 | $5K | |
| 84100 | <1% | 2,445 | $5K | |
| 87210 | <1% | 834 | $5K | |
| 86880 | <1% | 265 | $5K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 46 | $4K |
| 86703 | <1% | 489 | $4K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,432 | $4K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,799 | $4K |
| 72158 | <1% | 15 | $4K | |
| 83540 | <1% | 1,141 | $4K | |
| 86803 | <1% | 461 | $4K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 37 | $4K |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 47 | $4K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 116 | $4K |
| 97542 | <1% | 114 | $4K | |
| 82330 | <1% | 814 | $4K | |
| 86780 | <1% | 418 | $4K | |
| 87075 | <1% | 647 | $4K | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 354 | $4K |
| 83550 | <1% | 1,128 | $4K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 139 | $4K |
| 76882 | <1% | 33 | $4K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 25 | $4K |
| 74420 | <1% | 20 | $4K | |
| 86923 | <1% | 100 | $3K | |
| 87205 | <1% | 1,049 | $3K | |
| 87186 | <1% | 1,156 | $3K | |
| 76775 | <1% | 40 | $3K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 54 | $3K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,824 | $3K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 502 | $3K |
| 77065 | Tomosynthesis, mammo | <1% | 267 | $3K |
| 71101 | <1% | 161 | $3K | |
| 76813 | <1% | 33 | $3K | |
| 82570 | <1% | 829 | $3K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 901 | $3K |
| 73090 | <1% | 278 | $3K | |
| 93298 | <1% | 574 | $3K | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 80 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,091 | $3K |
| 87340 | <1% | 560 | $3K | |
| 73564 | <1% | 28 | $3K | |
| 88302 | <1% | 57 | $3K | |
| C1782 | Morcellator | <1% | 35 | $3K |
| 92526 | <1% | 100 | $3K | |
| 73552 | <1% | 244 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,804 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 912 | $2K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,028 | $2K |
| 83615 | <1% | 1,111 | $2K | |
| 12002 | <1% | 18 | $2K | |
| 86038 | <1% | 79 | $2K | |
| 80069 | <1% | 361 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,267 | $2K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 843 | $2K |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | <1% | 114 | $2K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 666 | $2K |
| 82977 | <1% | 1,343 | $2K | |
| 93356 | <1% | 29 | $2K | |
| 73522 | <1% | 39 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,462 | $2K |
| 89051 | <1% | 109 | $2K | |
| 88360 | <1% | 13 | $2K | |
| 82550 | <1% | 807 | $2K | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 612 | $2K |
| J1836 | Injection, metronidazole, 10 mg | <1% | 746 | $2K |
| 85384 | <1% | 509 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,153 | $2K |
| 82010 | <1% | 658 | $2K | |
| 84550 | <1% | 1,033 | $1K | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 290 | $1K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 943 | $1K |
| 73060 | <1% | 152 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 62 | $1K |
| 84156 | <1% | 723 | $1K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 587 | $1K |
| J7999 | Compounded drug, not otherwise classified | <1% | 626 | $1K |
| 80164 | <1% | 402 | $1K | |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 550 | $1K |
| 85007 | <1% | 352 | $1K | |
| 72157 | <1% | 21 | $1K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 369 | $1K |
| C1729 | Catheter, drainage | <1% | 312 | $1K |
| 84145 | <1% | 100 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,247 | $1K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 692 | $1K |
| 74230 | <1% | 21 | $1K | |
| 80177 | <1% | 292 | $1K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 968 | $1K |
| 86870 | <1% | 17 | $1K | |
| 82784 | <1% | 435 | $1K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 452 | $1K |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 661 | $1K |
| 82140 | <1% | 453 | $1K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 742 | $1K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 612 | $1K |
| 80329 | <1% | 69 | $997.92 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,794 | $986.29 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,968 | $952.12 |
| 86704 | <1% | 72 | $928.31 | |
| 84132 | <1% | 594 | $911.87 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,030 | $860.60 |
| 87641 | <1% | 18 | $821.08 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,037 | $779.16 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 2,242 | $773.56 |
| 88112 | <1% | 52 | $738.34 | |
| 83970 | <1% | 81 | $674.08 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 415 | $670.06 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 117 | $668.18 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 692 | $637.32 |
| 86592 | <1% | 234 | $569.90 | |
| 84295 | <1% | 339 | $565.04 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 57 | $553.07 |
| 85018 | <1% | 713 | $552.73 | |
| 86706 | <1% | 64 | $532.70 | |
| 87420 | <1% | 14 | $488.08 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 375 | $484.38 |
| 85045 | <1% | 296 | $472.60 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 169 | $472.11 |
| 92611 | <1% | 21 | $470.56 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 197 | $469.22 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 438 | $448.50 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 307 | $441.69 |
| 86200 | <1% | 17 | $415.27 | |
| 76942 | <1% | 121 | $361.26 | |
| 84450 | <1% | 141 | $349.09 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 60 | $337.60 |
| 84460 | <1% | 139 | $329.06 | |
| 86235 | <1% | 16 | $297.85 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 411 | $297.10 |
| 86431 | <1% | 15 | $294.03 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,668 | $276.65 |
| J2359 | Injection, olanzapine, 0.5 mg | <1% | 26 | $266.74 |
| 87147 | <1% | 37 | $220.84 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 26 | $207.86 |
| 82375 | <1% | 53 | $165.24 | |
| 80074 | <1% | 33 | $128.07 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 148 | $123.80 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 17 | $118.14 |
| 51701 | <1% | 122 | $111.78 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 72 | $106.92 |
| 83050 | <1% | 36 | $97.20 | |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | <1% | 123 | $92.28 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 188 | $82.32 |
| 82435 | <1% | 131 | $74.73 | |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 182 | $64.01 |
| 82803 | <1% | 13 | $48.15 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 52 | $47.41 |
| 82150 | <1% | 28 | $45.75 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 52 | $42.60 |
| 84425 | <1% | 20 | $40.29 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 113 | $39.87 |
| 86308 | <1% | 18 | $32.58 | |
| 82310 | <1% | 19 | $27.18 | |
| 80175 | <1% | 14 | $26.28 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 13 | $11.14 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 28 | $3.40 |
| 84155 | <1% | 13 | $1.80 | |
| 87176 | 0% | 17 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 21 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 17 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 208 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 15 | $0.00 |
| 84134 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBROWNING, MICHAEL (CFO, OHIOHEALTH)
Parent organizationOHIO HEALTH CORPORATION
| Provider | Location | Paid |
|---|---|---|
| Ohiohealth Corporation | Columbus, OH | $214.99M |
| Ohiohealth Corporation | Columbus, OH | $72.29M |
| Ohiohealth Corporation | Columbus, OH | $44.08M |
| Medcentral Health System | Mansfield, OH | $36.92M |
| Marion General Hospital, INC. | Marion, OH | $36.47M |
| Sheltering Arms Hospital Foundation, INC. | Athens, OH | $26.88M |
| Ohiohealth Berger Hospital LLC | Circleville, OH | $16.38M |
| Ohiohealth Corporation | Dublin, OH | $11.81M |
| Grady Memorial Hospital | Delaware, OH | $9.51M |
| Hardin Memorial Hospital | Kenton, OH | $7.27M |
| Medcentral Health System | Mansfield, OH | $3.13M |
| Madison Family Health Corporation | London, OH | $1.03M |
| Marion General Hospital, INC. | Marion, OH | $683K |
| Medcentral Health System | Mansfield, OH | $477K |
| Sheltering Arms Hospital Foundation | Athens, OH | $435K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.